# PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

> **NCT05387070** · PHASE3 · COMPLETED · sponsor: **Visen Pharmaceuticals (Shanghai) Co., Ltd.** · enrollment: 81 (actual)

## Conditions studied

- Hypoparathyroidism
- Parathyroid Hormone Deficiency
- Endocrine System Diseases
- Parathyroid Diseases

## Interventions

- **DRUG:** TransCon PTH
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05387070
- **Lead sponsor:** Visen Pharmaceuticals (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2023-01-04
- **Final completion:** 2026-01-08
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05387070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05387070, "PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05387070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*